

Pandemic Vaccine Prep

The case for a government-led response

Equities
Pharmaceuticals

- ◆ Developing a vaccine against a new virus that causes a pandemic is not just about discovering one and doing trials
- ◆ The availability of manufacturing capacity – and enough of it – is key; there are only five global vaccine manufacturers
- ◆ In our view, a co-ordinated government-funded increase in vaccine manufacturing capacity is needed

Discover, develop, manufacture: It is not easy or straightforward to discover a new vaccine and develop it through clinical studies. Furthermore, being able to manufacture a vaccine – and at scale – is a complex process that can take years to put in place.

We believe a co-ordinated response for future pandemics is needed or history repeats itself: The majority of vaccine manufacturing capacity (and know-how) for global vaccine development and manufacturing resides in Europe. If a pandemic vaccine(s) were developed and manufactured in Europe, Europe would get the vaccine first ahead of the US, Asia and elsewhere. **Further, lack of preparation now for future pandemics could result in a repeat of the COVID-19 financial fall-out.**

Governments ideally would fund vaccine manufacturing capacity: Since the **financial incentives for the private sector to build that capacity are simply not there** (and private sector activities are not co-ordinated), in our view, it would be preferable for governments to co-ordinate and fund the cost of building and maintaining vaccine manufacturing capabilities over the long term. Such facilities should be able to produce sub-unit vaccines, antibodies, inactivated vaccines and attenuated live vaccines, we believe.

In an optimal structure, the vaccine companies, not governments or supra-national organisations, would be in charge, in our view: Vaccine manufacturing capabilities and know-how reside in a small number of companies that can manufacture a wide variety of vaccines at scale. We think it is those companies that are best placed to build and run new facilities for pandemic vaccines. These companies could utilise that manufacturing capacity for the production of other vaccines in between making pandemic vaccines to maintain the facility or facilities and optimise manufacturing processes.

What's in it for governments? 1. The ability to manufacture a new vaccine relatively quickly – and for it to be manufactured by vaccine experts – once the vaccine has been discovered and trialed; 2. **the avoidance of repeated significant financial and social consequences by being able to respond to a pandemic more quickly**; 3. the certainty that a vaccine can be manufactured when otherwise the financial incentives for the private sector are absent (due to high initial costs/ongoing capex with no certainty of generating an economic return).

Steve McGarry*
Global Head of Healthcare Research
HSBC Bank plc

Julie Mead*
Analyst
HSBC Bank plc

** Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/ qualified pursuant to FINRA regulations*

Disclosures & Disclaimer

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

Issuer of report: HSBC Bank plc

View HSBC Global Research at:
<https://www.research.hsbc.com>

Insurance against future pandemics

- ◆ Globally there could be future pandemics due to different viruses with repeated financial fall-out
- ◆ But the financial incentives for the private sector to prepare for such uncertain events are simply not there
- ◆ In our view, vaccine manufacturing should be built now – ideally paid for by governments, run by vaccine companies – to prepare for future pandemics

Insurance against future pandemics and resulting financial fallout

The COVID-19 global pandemic is unprecedented in modern times, especially in its economic and social impact (see numerous notes from HSBC's Economics research team, including *Global Economics: Shockdown*, 2 April 2020). In our view, given the scale of the financial impact, governments need to consider preparing for future pandemics, however unlikely they may be to occur. **As such, we believe unprecedented action to enlist the help of vaccine companies and to pay for it – now – to build sufficient vaccine manufacturing capacity, is needed.**

Cost to prepare for multiple future pandemics

USD 20bn

Cost of current pandemic

USD multi-trn

Source: HSBC estimates

Although COVID-19 is the first major modern pandemic and it may be too late for this outbreak to develop a vaccine that could be administered widely (the virus may have run its course by the time any vaccine candidate might be developed; alternatively, it could be seasonal or remain active permanently), **we believe it would be prudent to plan for further pandemics in the future caused by other viruses.** The private sector (pharma companies with vaccine divisions) has a role to play since it has the expertise and know-how to manufacture vaccines and manufacture them at scale. **However, for preparations for future virus-driven pandemics (NB plural) – which may or may not happen and may or may not require a vaccine, which**

means the economics for pharma companies do not work – **a government-led proposition would be the best option, in our view.**

The incentives for governments to act, given the economic damage occurring in real-time and on a global basis, are significant. Although we estimate the cost of building vaccine manufacturing capacity on a global scale could reach USD10-20bn (including maintenance costs over the long term), it pales into insignificance relative to the economic and social costs of not being prepared for further pandemics and especially if those costs were shared on a multi-national basis.

Why a private-sector solution cannot be relied upon

There could be repeated, multiple pandemics in the future that individually could reap significant economic harm, but as each pandemic could be relatively limited, the financial incentives for pharmaceutical companies to prepare for multiple pandemics are simply not there.

Pharmaceutical companies need to invest for relatively certain financial returns, not for uncertain events that might mean they incur relatively certain losses or highly uncertain returns. **As such, although the private sector has the capabilities to deal with multiple pandemics, it does not necessarily have the financial incentives to do so.**

Further, although COVID-19 has now infected over 2m people globally and has a much greater mortality than seasonal influenza (currently c. 6.7% vs 0.1%; source Johns Hopkins University), it is not clear how many doses of vaccine would be needed in this or any future pandemic. Unlike seasonal influenza for which over 200m doses of vaccine are produced annually (which is cost-effective for several companies), a vaccine against COVID-19 or any subsequent pandemic virus may require a much lower level of dosing that would make it economically unviable for pharmaceutical companies to make build manufacturing capabilities for such scenarios.

Vaccine manufacturing is key and takes time

During this pandemic several companies have announced plans to develop a significant number of vaccines against COVID-19 (also potential therapeutics). **Aside from the challenges of developing a safe and effective vaccine (for example, there is still no vaccine against SARS or HIV after 20-30 years, respectively), these announcements ignore the fact that if a traditional vaccine that was safe and effective was developed, it could not be manufactured in the short term or on a large scale.**

Vaccine manufacturing is complex and can take over five years (usually more) to put in place. The upfront capex involved is significant, the ongoing capex is also notably higher than for traditional (small molecule) drug manufacturing and the payback period for companies developing and manufacturing vaccines is also prolonged relative to other drugs and can be economically unviable. The safety of vaccines, which is also governed by the manufacturing process, is key since vaccines are administered to otherwise healthy individuals, including to children and to those who are more vulnerable – people with pre-existing medical conditions (so the tolerance of side effects is low). Quality control plays a large part in ensuring vaccine safety, with over 100 quality or safety checks for every vaccine before it can be administered to a patient (Sanofi, for example, estimates that 70% of vaccine production time is dedicated to quality tests). **Even when manufacturing processes have been put in place and optimised, the manufacturing process for some vaccines can last 18-36 months.**

As an example, Pfizer notes that the manufacture of its Prevnar 13 vaccine (against pneumococcal bacteria) involves:

- ◆ 1,700 employees
- ◆ 678 quality tests
- ◆ 400 different raw materials
- ◆ 580 manufacturing steps
- ◆ 2.5 years to manufacture

Global vaccine manufacturing know-how is concentrated


Global vaccine manufacturing know-how and global manufacturing scale are concentrated in only five companies:

- ◆ GlaxoSmithKline (UK)
- ◆ Sanofi (France)
- ◆ Merck & Co (US)
- ◆ Pfizer (US, although mainly for one vaccine)
- ◆ Seqirus (UK, a subsidiary of CSL)

Further, vaccine manufacturing that generates the sales of the majority of vaccines globally has a high presence in Europe, with GSK's two main manufacturing facilities in Wavre and Rixensart in Belgium, Marburg in Germany and Siena in Italy, and Sanofi's at Val-de-Reuil, Marcy L'Etoile and Neuville-sur-Saone in France. Although both companies and other vaccine companies also have facilities elsewhere, there is a disproportionate concentration of vaccine manufacturing capabilities in Europe versus the US and Asia, for example.

In Asia, there are multiple local vaccine manufacturers in India, China and elsewhere. Aside from a limited number of companies in these territories, eg Serum Institute of India, Bharat Biotech, most manufacturers produce a limited number of vaccines in relatively small volumes overall. **In contrast, GlaxoSmithKline and Sanofi alone produce over 40 different types of vaccine and in 2019 produced over 1.7bn doses of vaccines.**

Existing manufacturing facilities are generally utilised for the manufacture of vaccines that are needed and therefore cannot be re-purposed for the manufacture of a pandemic vaccine. There is little spare capacity in the industry and there are examples of the need for extra manufacturing capacity, as shown by GSK's need for further Shingrix capacity and the inability of bodies such as the Developing Countries Vaccine Manufacturers Network (DCVMN) being unable to keep up with demand for current vaccines. **Hence, we think pandemic vaccine manufacturing capabilities – especially at scale – would need to be built.**

Global vaccine sales by the top 5 manufacturers (USDm)


Source: Company data, HSBC estimates, Bloomberg

So there is a need to prepare...and the need for government funding, in our view

Given the challenges outlined above, in our view governments would need to enlist vaccine companies to prepare for future virus pandemics. We estimate that building pandemic vaccine manufacturing capabilities would require at least two sites and cost up to c. USD20bn over say a 20-year period (including initial capex and maintenance capex costs). **Given the un-coordinated private sector response to COVID-19, we suggest it would be better for multiple governments to consider funding the building of that capacity, as part of a co-ordinated effort to mitigate the repeated medical, social and financial consequences of future pandemics (and potentially COVID-19 as well).**

Manufacturing mechanism

We think such manufacturing facilities ideally would be built and run by nominated vaccine companies since they have the expertise and know-how. Such facilities could be leased to the nominated vaccine companies on a perpetual lease for zero rent. Although the construction and running costs might be paid for by multiple governments, the nominated companies – as part payment for their expertise and know-how – could utilise the manufacturing capacity to manufacture other vaccines (which would also maintain the facilities and allow optimisation of processes), but might be required to switch manufacturing to the pandemic vaccine or alternatively, they might be required to keep a proportion of the manufacturing capacity idling for pandemic vaccine preparation. In our view, the facilities would have to be capable of manufacturing sub-unit vaccines, antibodies, inactivated vaccines and live attenuated vaccines and have all the necessary downstream processing as well as fill-and-finish capabilities, ie the whole range of potential vaccine therapeutics that might be developed in due course.

What governments would gain

Certainty that a vaccine could be manufactured

Avoidance of repeated economic and social damage

What vaccine companies would gain

Additional manufacturing capacity for no extra cost that could likely be utilised between pandemics for prolonged periods of time

Pandemic vaccine manufacturing Q&A

Likely questions on our proposal and our answers:

1. Q. Who would fund the vaccine manufacturing capacity?
A. Multiple governments.
2. Q. Who would own the manufacturing facility/facilities?
A. There would be shared ownership commensurate to each country's contribution to construction and maintenance costs and with a perpetual lease granted to the nominated Vaccine company/companies.
3. Q. What if one of the contributing countries stopped paying their share of the ongoing costs?
A. There would have to be a penalty clause that would restrict access to manufactured vaccines if any country defaulted on their share of the ongoing costs.
4. Q. Which countries would get the pandemic vaccines first?
A. Distribution of manufactured vaccines would ideally be on a geographic and medical basis, with the most vulnerable individuals and countries prioritised. For example, at an outbreak of a pandemic in one country, it could be prioritised with vulnerable individuals in other countries also being vaccinated initially and with broader distribution to other countries and the wider population later as stocks become available. However, recognising that this might be a politically sensitive issue, distribution could be on the basis of percentage of the vaccine stock at a time to each country proportionate to their population.

The JNJ/BARDA plan – a US-centric solution?

Johnson & Johnson – a small player in the vaccines area – announced a collaboration with the US BARDA (Biological Advanced Research and Development Authority) to jointly commit USD1bn to research and develop a new vaccine against COVID-19 and to build manufacturing capacity for the vaccine. First, there is no guarantee that the first vaccine candidate will be effective or safe. Secondly, even if approved under emergency authorisation by 2021, we think it is unlikely that there would be sufficient manufacturing capacity available to produce the vaccine en masse. Thirdly, by building US manufacturing capacity in collaboration with a US government agency, it would probably ensure that the US population would preferentially gain access to any vaccine that was developed. That is not an unusual situation (cf smallpox vaccine manufacturing post-9/11), but it does add a US-centricity on any developed vaccine for a global problem. **As we noted earlier, in the absence of a co-ordinated response, vaccine development for COVID-19 and for future pandemics could easily become “everyone for themselves”.**

Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), or strategist(s) who is(are) primarily responsible for this report, including any analyst(s) whose name(s) appear(s) as author of an individual section or sections of the report and any analyst(s) named as the covering analyst(s) of a subsidiary company in a sum-of-the-parts valuation certifies(y) that the opinion(s) on the subject security(ies) or issuer(s), any views or forecasts expressed in the section(s) of which such individual(s) is(are) named as author(s), and any other views or forecasts expressed herein, including any views expressed on the back page of the research report, accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Steve McGarry and Julie Mead

Important disclosures

Equities: Stock ratings and basis for financial analysis

HSBC and its affiliates, including the issuer of this report ("HSBC") believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations and that investors utilise various disciplines and investment horizons when making investment decisions. Ratings should not be used or relied on in isolation as investment advice. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations and therefore investors should carefully read the definitions of the ratings used in each research report. Further, investors should carefully read the entire research report and not infer its contents from the rating because research reports contain more complete information concerning the analysts' views and the basis for the rating.

From 23rd March 2015 HSBC has assigned ratings on the following basis:

The target price is based on the analyst's assessment of the stock's actual current value, although we expect it to take six to 12 months for the market price to reflect this. When the target price is more than 20% above the current share price, the stock will be classified as a Buy; when it is between 5% and 20% above the current share price, the stock may be classified as a Buy or a Hold; when it is between 5% below and 5% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold or a Reduce; and when it is more than 20% below the current share price, the stock will be classified as a Reduce.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation or resumption of coverage, change in target price or estimates).

Upside/Downside is the percentage difference between the target price and the share price.

Prior to this date, HSBC's rating structure was applied on the following basis:

For each stock we set a required rate of return calculated from the cost of equity for that stock's domestic or, as appropriate, regional market established by our strategy team. The target price for a stock represented the value the analyst expected the stock to reach over our performance horizon. The performance horizon was 12 months. For a stock to be classified as Overweight, the potential return, which equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated, had to exceed the required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile*). Stocks between these bands were classified as Neutral.

*A stock was classified as volatile if its historical volatility had exceeded 40%, if the stock had been listed for less than 12 months (unless it was in an industry or sector where volatility is low) or if the analyst expected significant volatility. However, stocks which we did not consider volatile may in fact also have behaved in such a way. Historical volatility was defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility had to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.

Rating distribution for long-term investment opportunities

As of 17 April 2020, the distribution of all independent ratings published by HSBC is as follows:

Buy	55%	(31% of these provided with Investment Banking Services)
Hold	36%	(30% of these provided with Investment Banking Services)
Sell	9%	(25% of these provided with Investment Banking Services)

For the purposes of the distribution above the following mapping structure is used during the transition from the previous to current rating models: under our previous model, Overweight = Buy, Neutral = Hold and Underweight = Sell; under our current model Buy = Buy, Hold = Hold and Reduce = Sell. For rating definitions under both models, please see “Stock ratings and basis for financial analysis” above.

For the distribution of non-independent ratings published by HSBC, please see the disclosure page available at <http://www.hsbcnet.com/gbm/financial-regulation/investment-recommendations-disclosures>.

To view a list of all the independent fundamental ratings disseminated by HSBC during the preceding 12-month period, please use the following links to access the disclosure page:

Clients of Global Research and Global Banking and Markets: www.research.hsbc.com/A/Disclosures

Clients of HSBC Private Banking: www.research.privatebank.hsbc.com/Disclosures

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

Non-U.S. analysts may not be associated persons of HSBC Securities (USA) Inc, and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with the subject company, public appearances and trading securities held by the analysts.

Economic sanctions imposed by the EU and OFAC prohibit transacting or dealing in new debt or equity of Russian SSI entities. This report does not constitute advice in relation to any securities issued by Russian SSI entities on or after July 16 2014 and as such, this report should not be construed as an inducement to transact in any sanctioned securities.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research. HSBC Private Banking clients should contact their Relationship Manager for queries regarding other research reports. In order to find out more about the proprietary models used to produce this report, please contact the authoring analyst.

Additional disclosures

- 1 This report is dated as at 20 April 2020.
- 2 All market data included in this report are dated as at close 17 April 2020, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.

Production & distribution disclosures

1. This report was produced and signed off by the author on 17 Apr 2020 16:47 GMT.
2. In order to see when this report was first disseminated please see the disclosure page available at <https://www.research.hsbc.com/R/34/WcvBf2T>

Disclaimer

Legal entities as at 11 February 2020

'UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Securities (Canada) Inc.; HSBC France, S.A., Madrid, Milan, Stockholm; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch; PT Bank HSBC Indonesia; HSBC Qianhai Securities Limited; HSBC Brasil S.A. – Banco de Investimento

Issuer of report

HSBC Bank plc
8 Canada Square
London, E14 5HQ, United Kingdom
Telephone: +44 20 7991 8888
Fax: +44 20 7992 4880
Website: www.research.hsbc.com

In the UK this document has been issued and approved by HSBC Bank plc ("HSBC") for the information of its Clients (as defined in the Rules of FCA) and those of its affiliates only. It is not intended for Retail Clients in the UK. If this research is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. Only Economics or Currencies reports are intended for distribution to a person who is not an Accredited Investor, Expert Investor or Institutional Investor as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch accepts legal responsibility for the contents of reports pursuant to Regulation 32C(1)(d) of the Financial Advisers Regulations. This publication is not a prospectus as defined in the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. Please refer to The Hongkong and Shanghai Banking Corporation Limited Singapore Branch's website at www.business.hsbc.com.sg for contact details.

In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162, AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient.

This publication has been distributed in Japan by HSBC Securities (Japan) Limited. It may not be further distributed, in whole or in part, for any purpose. In Hong Kong, this document has been distributed by The Hongkong and Shanghai Banking Corporation Limited in the conduct of its Hong Kong regulated business for the information of its institutional and professional customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited makes no representations that the products or services mentioned in this document are available to persons in Hong Kong or are necessarily suitable for any particular person or appropriate in accordance with local law. All inquiries by such recipients must be directed to The Hongkong and Shanghai Banking Corporation Limited. In Korea, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. HBAP SLS is regulated by the Financial Services Commission and the Financial Supervisory Service of Korea. This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without notice. From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits. Nothing herein excludes or restricts any duty or liability to a customer which HSBC has under the Financial Services and Markets Act 2000 or under the Rules of FCA and PRA. A recipient who chooses to deal with any person who is not a representative of HSBC in the UK will not enjoy the protections afforded by the UK regulatory regime. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed.

In Canada, this document has been distributed by HSBC Securities (Canada) Inc. (member IIROC), and/or its affiliates. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offense. In Brazil, this document has been distributed by HSBC Brasil S.A. – Banco de Investimento ("HSBC Brazil"), and/or its affiliates. As required by Instruction No. 598/18 of the Securities and Exchange Commission of Brazil (Comissão de Valores Mobiliários), potential conflicts of interest concerning (i) HSBC Brasil and/or its affiliates; and (ii) the analyst(s) responsible for authoring this report are stated on the chart above labelled "HSBC & Analyst Disclosures".

HSBC Bank plc is registered in England No 14259, is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange. (070905)

If you are an HSBC Private Banking ("PB") customer with approval for receipt of relevant research publications by an applicable HSBC legal entity, you are eligible to receive this publication. To be eligible to receive such publications, you must have agreed to the applicable HSBC entity's terms and conditions ("KRC Terms") for access to the KRC, and the terms and conditions of any other internet banking service offered by that HSBC entity through which you will access research publications using the KRC. Distribution of this publication is the sole responsibility of the HSBC entity with whom you have agreed the KRC Terms.

If you do not meet the aforementioned eligibility requirements please disregard this publication and, if you are a customer of PB, please notify your Relationship Manager. Receipt of research publications is strictly subject to the KRC Terms, which can be found at <https://research.privatebank.hsbc.com/> – we draw your attention also to the provisions contained in the Important Notes section therein.

© Copyright 2020, HSBC Bank plc, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC Bank plc. MCI (P) 077/12/2019, MCI (P) 016/02/2020

[1144671]